Bio-IT World March 23, 2021

TRENDS FROM THE TRENCHES—It’s been a little over a year since Eric Dishman stepped down as CEO of the National Institutes of Health’s All of Us program and took on the role of Chief Innovation Officer. Before his time building the All of Us research program, Dishman served as an Intel fellow and vice president of the Health and Life Sciences Group at Intel Corporation.

But when he sat down to catch up with Stan Gloss, founding partner at the BioTeam, he credited much of his innovative thinking to even earlier experiences: his own 23-year journey as a cancer patient—finally cured thanks to precision medicine; his internship at Paul Allen’s think tank, Interval; and his early training in acting...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Interview / Q&A, Patient / Consumer, Pharma / Biotech, Precision Medicine, Provider, Trends
Exploring the potential of personalized precision medicine for healthcare industry
Putting Patients First by Extending the Reach of World-Class Care
Healthcare's most promising tech
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce

Share This Article